AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
Part of paid clinical trials in Orlando, Florida.
- Sponsor
- AdventHealth Translational Research Institute
- Study ID
- NCT04807868
- Status
- Recruiting
Conditions
- Non-Alcoholic Fatty Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Standard of care liver biopsy — PROCEDUREPatients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
- Fibroscan — OTHERA FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
- Biospecimen Collection — OTHERBlood and urine will be collected.
Study Details
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
Key Dates
- Start date
- Apr 22, 2021
- Status verified
- Mar 2025
- Primary completion
- Dec 31, 2025
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 1,250 participants (estimated)
Arms
- Arm: Biopsy GroupAdults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
- Arm: Non-Biopsy GroupAdults without any history of NAFLD
Primary Outcome Measure
Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata [ Time Frame: Baseline ]
Central Contacts
- Recruitment Department407-303-7100
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| AdventHealth Translational Research Institute | Orlando | Florida | 32804 |
Find similar trials in Orlando, FL
By research site
Related Studies
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPHASE3 · Recruiting · GlaxoSmithKline · Arcadia, California
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPHASE3 · Recruiting · GlaxoSmithKline · Arcadia, California
- A Study of Efimosfermin Alfa in Adults With Hepatic ImpairmentPHASE1 · Recruiting · GlaxoSmithKline · Rialto, California
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois